KR930004597B1 - 과립구 콜로니 자극인자를 함유하는 안정한 약제 및 그의 제조방법 - Google Patents
과립구 콜로니 자극인자를 함유하는 안정한 약제 및 그의 제조방법Info
- Publication number
- KR930004597B1 KR930004597B1 KR1019870007804A KR870007804A KR930004597B1 KR 930004597 B1 KR930004597 B1 KR 930004597B1 KR 1019870007804 A KR1019870007804 A KR 1019870007804A KR 870007804 A KR870007804 A KR 870007804A KR 930004597 B1 KR930004597 B1 KR 930004597B1
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- granulocyte colony
- csf
- molecular weight
- polyoxyethylene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
- 유효성분으로서 존재하는 과립구 콜로니 자극인자 외에도, 약제학적으로 허용가능한 계면활성제, 당류, 단백질 및 고분자량 화합물로 이루어진 군으로부터 선택되는 1종 이상의 물질을 함유함을 특징으로 하는 안정한 과립구 콜로니 자극인자-함유 약제.
- 제1항에 있어서, 과립구 콜로니 자극인자의 중량부당 1∼10,000중량부의 양으로 계면활성제를 함유하는 안정한 과립구 콜로니 자극인자-함유 약제.
- 제1 또는 2항에 있어서, 상기의 계면활성제가 소르비탄 지방족산 에스테르, 글리세린 지방족산 에스테르, 폴리글리세린 지방족산 에스테르, 폴리옥시에틸렌 소르비탄 지방족산 에스테르, 폴리옥시에틸렌 소르비톨 지방족산 에스테르, 폴리옥시에틸렌 글리세린 지방족산 에스테르, 폴리에틸렌글리콜 지방족산 에스테르, 폴리옥시에틸렌 알킬에테르, 폴리옥시에틸렌 폴리옥시프로필렌 알킬에테르, 폴리옥시에틸렌 알킬페닐에테르, 경화된 폴리옥시에틸화 캐스터오일, 폴리옥시에틸화 밀랍 유도체, 폴리옥시에틸렌 라놀린 유도체 또는 폴리옥시에틸렌지방족산 아미드와 같은 비이온성 계면활성제 ; 알킬황산염, 폴리옥시에틸렌 알킬에테르 황산염 또는 알킬술포숙시네이트 에스테르 염과 같은 음이온성 계면활성제 ; 및 레시틴, 글리세로포스포리피드, 스핀고포스포리피드 또는 슈크로오즈 지방족산 에스테르와 같은 천연 계면활성제로 이루어진 군으로부터 선택된 1종 이상의 물질인 안정한 과립구 콜로니 자극인자-함유 약제.
- 제1항에 있어서, 과립구 콜로니 자극인자의 중량부당 1∼10,000중량부의 양으로 당류를 함유하는 안정한 과립구 콜로니 자극인자-함유 약제.
- 제1 또는 4항에 있어서, 상기의 당류가 글리세린, 에리트리톨, 아라비톨, 크실리톨, 소르비톨, 만니톨, 글루쿠론산, 이두론산, 갈락투론산, 뉴라민산, 글리콘산, 만누론산, 케토글리콜산, 케토갈락톤산, 케토글루콘산, 히알루론산 및 그의 염, 황산콘드로이틴 및 그의 염, 헤파린, 이눌린, 키틴 및 그의 유도체, 키토산 및 그의 유도체, 덱스트린, 5,000∼150,000의 평균 분자량을 갖는 덱스트란 및 아르긴산 및 그의 염으로 이루어진 군으로부터 선택된 1종 이상의 물질인 안정한 과립구 콜로니 자극인자-함유 약제.
- 제1항에 있어서, 과립구 콜로니 자극인자의 중량부당 1∼20,000중량부의 양으로 단백질을 함유하는 안정한 과립구 콜로니 자극인자-함유 약제.
- 제1 또는 6항에 있어서, 상기의 단백질이 인체 혈청 알부민, 인체혈청 글로불린, 젤라틴, 7,000∼100,000의 평균분자량을 갖는 산 또는 알칼리-처리된 젤라틴 및 콜라겐으로 이루어진 군으로부터 선택되는 1종 이상의 물질인 안정한 과립구 콜로니 자극인자-함유 약제.
- 제1항에 있어서, 과립구 콜로니 자극인자의 중량부당 1∼20,000중량부의 양으로 고분자량 화합물을 함유하는 안정한 과립구 콜로니 자극인자-함유 약제.
- 제1 또는 8항에 있어서, 상기의 고분자량 화합물이 히드록시프로필 셀룰로오스, 히드록시메틸셀룰로오스, 소듐카르복시메틸셀룰로우스, 히드록시에틸셀룰로오스, 300∼6,000의 분자량을 갖는 폴리에틸렌글리콜, 20,000∼100,000의 분자량을 갖는 폴리비닐알코올 및 20,000∼100,000의 분자량을 갖는 폴리비닐피롤리돈으로 이루어진 군으로부터 선택되는 1종 이상의 것인 안정한 과립구 콜로니 자극인자-함유 약제.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16948986 | 1986-07-18 | ||
JP169489 | 1986-07-18 | ||
JP16948786 | 1986-07-18 | ||
JP16948886 | 1986-07-18 | ||
JP16948686 | 1986-07-18 | ||
JP169488 | 1986-07-18 | ||
JP169486 | 1986-07-18 | ||
JP169487 | 1986-07-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR880001297A KR880001297A (ko) | 1988-04-22 |
KR930004597B1 true KR930004597B1 (ko) | 1993-06-01 |
Family
ID=27474266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019870007804A KR930004597B1 (ko) | 1986-07-18 | 1987-07-18 | 과립구 콜로니 자극인자를 함유하는 안정한 약제 및 그의 제조방법 |
Country Status (24)
Country | Link |
---|---|
KR (1) | KR930004597B1 (ko) |
CN (1) | CN1033738C (ko) |
AT (1) | AT402259B (ko) |
AU (1) | AU611856B2 (ko) |
BE (1) | BE1000253A3 (ko) |
CA (1) | CA1297007C (ko) |
CH (1) | CH671157A5 (ko) |
DE (1) | DE3723781C2 (ko) |
DK (1) | DK171308B1 (ko) |
ES (1) | ES2010226A6 (ko) |
FR (1) | FR2601591B1 (ko) |
GB (1) | GB2193631B (ko) |
GR (1) | GR871067B (ko) |
HK (1) | HK64893A (ko) |
HU (1) | HU198627B (ko) |
IE (1) | IE60290B1 (ko) |
IL (1) | IL83220A (ko) |
IT (1) | IT1218927B (ko) |
NL (1) | NL192917C (ko) |
NO (1) | NO171828C (ko) |
PT (1) | PT85343B (ko) |
SE (1) | SE503312C2 (ko) |
SG (1) | SG64393G (ko) |
YU (1) | YU47543B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101340710B1 (ko) * | 2010-01-19 | 2013-12-12 | 한미사이언스 주식회사 | 지속형 과립구 콜로니 자극인자 결합체의 액상 제제 |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
NO179479C (no) * | 1988-03-11 | 1996-10-16 | Teikoku Seiyaku Kk | Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat |
US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
US5349052A (en) * | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
US5104651A (en) * | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
JP3249147B2 (ja) * | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | 生理活性蛋白含有経口製剤 |
EP0459516A1 (en) * | 1990-06-01 | 1991-12-04 | Kirin-Amgen, Inc. | Oral dosage form of biologically active proteins |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
FR2686900B1 (fr) * | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. |
FR2693907B1 (fr) * | 1992-07-23 | 1994-09-02 | Rhone Poulenc Rorer Sa | Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires. |
EP0582932A1 (de) * | 1992-08-11 | 1994-02-16 | F. Hoffmann-La Roche Ag | Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren |
DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
DE4242919A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF |
US20030053982A1 (en) | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
WO1996024369A1 (en) * | 1995-02-06 | 1996-08-15 | Genetics Institute, Inc. | Formulations for il-12 |
TW434021B (en) * | 1995-03-15 | 2001-05-16 | Kirin Brewery | Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions |
TW434020B (en) * | 1995-03-15 | 2001-05-16 | Kirin Brewery | Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
WO1999044630A1 (fr) * | 1998-03-06 | 1999-09-10 | Chugai Seiyaku Kabushiki Kaisha | Preparations exemptes de proteines |
US6979442B1 (en) * | 1998-08-17 | 2005-12-27 | Pfizer Inc. | Stabilized protein compositions |
TWI245645B (en) | 1999-09-08 | 2005-12-21 | Chugai Pharmaceutical Co Ltd | Protein solution formulations and stabilization methods thereof |
WO2001064241A1 (fr) * | 2000-02-29 | 2001-09-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a long terme |
ES2220673T3 (es) | 2000-02-29 | 2004-12-16 | Pfizer Products Inc. | Factor estimulante de colonias de granulocitos estabilizado. |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ES2484966T3 (es) | 2000-04-12 | 2014-08-12 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
AU2001282607B2 (en) * | 2000-09-01 | 2006-08-17 | Chugai Seiyaku Kabushiki Kaisha | Solution preparations stabilized over long time |
US8435939B2 (en) | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2426139B1 (en) | 2002-08-27 | 2014-10-01 | Biokine Therapeutics Ltd. | CXCR4 antagonist and use thereof |
WO2004075913A1 (ja) | 2003-02-28 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | タンパク質含有安定化製剤 |
DE202006020194U1 (de) | 2006-03-01 | 2007-12-06 | Bioceuticals Arzneimittel Ag | G-CSF-Flüssigformulierung |
EP2759302A3 (en) | 2006-12-21 | 2014-11-05 | Biokine Therapeutics LTD. | 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour |
WO2010092571A2 (en) | 2009-02-11 | 2010-08-19 | Yeda Research And Development Co. Ltd. | Short beta-defensin-derived peptides |
EP2399572A1 (en) | 2010-06-22 | 2011-12-28 | Sandoz AG | Long-term storage of non-glycosylated recombinant human G-CSF |
EP3744340A3 (en) | 2015-07-16 | 2021-03-03 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
AU2017222495B2 (en) | 2016-02-23 | 2019-08-08 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
WO2018138267A1 (en) | 2017-01-27 | 2018-08-02 | Cinfa Biotech S.L. | Method for determining the efficacy of a g-csf containing composition |
KR20210010996A (ko) * | 2018-05-21 | 2021-01-29 | 추가이 세이야쿠 가부시키가이샤 | 유리 용기에 봉입된 동결건조 제제 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2652636A1 (de) * | 1976-11-19 | 1978-05-24 | Hans Uwe Dr Rer Nat Wolf | Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung |
AU523077B2 (en) * | 1978-03-20 | 1982-07-08 | Green Cross Corporation, The | Hgi glycoprotein |
EP0098110B1 (en) * | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
JPS60228422A (ja) * | 1984-04-26 | 1985-11-13 | Suntory Ltd | 安定化された生理活性物質製剤 |
JPS61227526A (ja) * | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | 新規なコロニー刺激因子 |
JPS6191131A (ja) * | 1984-10-09 | 1986-05-09 | Chugai Pharmaceut Co Ltd | 医薬品の吸着防止方法および組成物 |
EP0211899B1 (en) * | 1985-02-05 | 1992-09-23 | Cetus Oncology Corporation | Purification of native colony stimulating factor-1 |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPH0618778B2 (ja) * | 1985-10-04 | 1994-03-16 | 中外製薬株式会社 | 白血球減少症治療剤 |
-
1987
- 1987-07-08 GR GR871067A patent/GR871067B/el unknown
- 1987-07-10 IT IT67594/87A patent/IT1218927B/it active
- 1987-07-13 NL NL8701640A patent/NL192917C/nl not_active IP Right Cessation
- 1987-07-14 AT AT0177587A patent/AT402259B/de not_active IP Right Cessation
- 1987-07-15 DK DK368387A patent/DK171308B1/da not_active IP Right Cessation
- 1987-07-15 CA CA000542239A patent/CA1297007C/en not_active Expired - Lifetime
- 1987-07-15 AU AU75665/87A patent/AU611856B2/en not_active Expired
- 1987-07-15 BE BE8700787A patent/BE1000253A3/fr not_active IP Right Cessation
- 1987-07-16 PT PT85343A patent/PT85343B/pt unknown
- 1987-07-16 CH CH2727/87A patent/CH671157A5/de not_active IP Right Cessation
- 1987-07-16 NO NO872966A patent/NO171828C/no not_active IP Right Cessation
- 1987-07-17 FR FR878710156A patent/FR2601591B1/fr not_active Expired - Lifetime
- 1987-07-17 DE DE3723781A patent/DE3723781C2/de not_active Expired - Lifetime
- 1987-07-17 GB GB8716904A patent/GB2193631B/en not_active Expired - Lifetime
- 1987-07-17 ES ES8702106A patent/ES2010226A6/es not_active Expired
- 1987-07-17 YU YU134287A patent/YU47543B/sh unknown
- 1987-07-17 HU HU873268A patent/HU198627B/hu unknown
- 1987-07-17 IL IL83220A patent/IL83220A/xx not_active IP Right Cessation
- 1987-07-17 SE SE8702907A patent/SE503312C2/sv not_active IP Right Cessation
- 1987-07-17 IE IE193387A patent/IE60290B1/en not_active IP Right Cessation
- 1987-07-18 KR KR1019870007804A patent/KR930004597B1/ko not_active IP Right Cessation
- 1987-07-18 CN CN87104963A patent/CN1033738C/zh not_active Expired - Lifetime
-
1993
- 1993-05-18 SG SG64393A patent/SG64393G/en unknown
- 1993-07-08 HK HK648/93A patent/HK64893A/xx not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101340710B1 (ko) * | 2010-01-19 | 2013-12-12 | 한미사이언스 주식회사 | 지속형 과립구 콜로니 자극인자 결합체의 액상 제제 |
US9867777B2 (en) | 2010-01-19 | 2018-01-16 | Hanmi Science Co., Ltd. | Liquid formulations for long-acting G-CSF conjugate |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930004597B1 (ko) | 과립구 콜로니 자극인자를 함유하는 안정한 약제 및 그의 제조방법 | |
US5919443A (en) | Stable lyophilized pharmaceutical preparations of G-CSF | |
AU2006235962A1 (en) | Solution formulations having long-term stability | |
JP3927248B2 (ja) | Hgf凍結乾燥製剤 | |
KR100389726B1 (ko) | 안정한 과립구 콜로니-자극 인자 함유 제제 | |
JP2577744B2 (ja) | 安定な顆粒球コロニ−刺激因子含有製剤 | |
JP2577742B2 (ja) | 安定な顆粒球コロニ−刺激因子含有製剤 | |
JP2577743B2 (ja) | 安定な顆粒球コロニ−刺激因子含有製剤 | |
JPS63146828A (ja) | 安定な顆粒球コロニ−刺激因子含有製剤 | |
JP2629000B2 (ja) | 安定な顆粒球コロニー刺激因子含有製剤 | |
EP0598905A1 (en) | STABILIZED IL-1$g(a) PHARMACEUTICAL PREPARATION | |
WO2023233277A1 (en) | Lyophilized pharmaceutical compositions of copper histidinate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
J204 | Request for invalidation trial [patent] | ||
J2X1 | Appeal (before the patent court) |
Free format text: INVALIDATION IN ENTIRETY |
|
J202 | Request for trial for correction [limitation] | ||
J202 | Request for trial for correction [limitation] | ||
J121 | Written withdrawal of request for trial | ||
J202 | Request for trial for correction [limitation] | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 19980618 Effective date: 19990225 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 19990206 Effective date: 20000531 |
|
J2X1 | Appeal (before the patent court) |
Free format text: CORRECTION |
|
J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR CORRECTION REQUESTED 20000712 Effective date: 20010209 |
|
J2X2 | Appeal (before the supreme court) |
Free format text: APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION IN ENTIRETY |
|
J2X2 | Appeal (before the supreme court) |
Free format text: APPEAL BEFORE THE SUPREME COURT FOR CORRECTION |
|
J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION IN ENTIRETY REQUESTED 19980608 Effective date: 20010209 |
|
J303 | Written judgement (supreme court) |
Free format text: JUDGMENT (SUPREME COURT) FOR CORRECTION REQUESTED 20010226 Effective date: 20021122 Free format text: JUDGMENT (SUPREME COURT) FOR INVALIDATION IN ENTIRETY REQUESTED 20010225 Effective date: 20021122 |
|
LAPS | Lapse due to unpaid annual fee |